ArticleThe Pan African medical journal2025
Prevalence of molecular markers associated with
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: currently, malaria (primarily caused by Plasmodium falciparum) remains prevalent in over 106 countries and is one of the most severe public health problems globally, leading the cause of deaths especially among children and pregnant women particularly in developing countries. This study determined the drug-resistance molecular markers in Plasmodium falciparum infection in three malaria endemic local areas of Benue State, North-central Nigeria between June 2023 and September 2024. Methods: the conclusive diagnosis of P. falciparum was based on identifying the characteristic asexual stage of the parasite in Giemsa-stained blood smears examined under a compound microscope. The DNA (Deoxyribonucleic acid) extraction from P. falciparum positive blood samples was done using Chelex extraction method. Nested polymerase chain reaction followed by Restriction Fragment Length Polymorphisms (PCR/RFLP) were used for the detection of Plasmodium falciparum Chloroquine resistance transporter (pfcrt), P. falciparum multidrug resistance 1 (pfmdr1), P. falciparum dihydrofolate reductase (pfdhfr) and P. falciparum dihydropteroate synthase (pfdhps). Data were analysed using SPSS Version 24.00 and inferences were drawn for Statistical significance at P<0.05. Results: the results revealed well-characterized molecular markers of P. falciparum resistance to the 4-aminoquinolines and the antifolate drugs indicating a high prevalence of resistance: 41%, 60%, 51% and 47% of P. falciparum isolates at codons N86Y, K76T, S108N, N51I and A437G respectively. Conclusion: the prevalence of resistance of isolates to antimalarial drugs was significantly high. Therefore, strategies to reduce multiple-strain infections should be implemented to improve antimalarial drug efficacy and reduce the rate of spread of drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.